Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sanjivani ParanteralsBOM:531569 -3.05%73 EBITDA Margin % is 16.45% as of Mar. 2026, which is 30% above its 10-year median of 12.65. GuruFocus rates BOM:531569 with a GF Score™ of 73/100 and a GF Value™ of ₹226.27 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 961 Drug Manufacturers companies, Sanjivani Paranterals ranks better than 60.56% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sanjivani Paranterals EBITDA Margin % Related Terms
Sanjivani Paranterals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sanjivani Paranterals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sanjivani Paranterals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanjivani Paranterals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanjivani Paranterals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sanjivani Paranterals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanjivani Paranterals (BOM:531569) has a EBITDA Margin % of 16.45% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sanjivani Paranterals and its competitors. This is 30% above median its historical median of 12.65. According to the industry distribution chart, Sanjivani Paranterals ranks #379 out of 961 companies in the Drug Manufacturers industry, placing it in the top 39.4%.
Is Sanjivani Paranterals' EBITDA Margin % too high?
Sanjivani Paranterals' current EBITDA Margin % of 16.45% is 30% above median its 10-year median of 12.65. The Drug Manufacturers industry median EBITDA Margin % is 12.45. Sanjivani Paranterals' value of 16.45% is 32.1% above this industry median. Based on the distribution chart, Sanjivani Paranterals ranks #379 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Sanjivani Paranterals has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sanjivani Paranterals' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sanjivani Paranterals ranks #379 out of 961 companies for EBITDA Margin %. This puts Sanjivani Paranterals in the upper half of its industry. The industry median EBITDA Margin % is 12.45. Sanjivani Paranterals' value of 16.45% is 32.1% above this benchmark. While the company's 10-year median is 12.65 vs. the industry median of 12.45, Sanjivani Paranterals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.45, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanjivani Paranterals's current EBITDA Margin % of 16.45% is 32.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sanjivani Paranterals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanjivani Paranterals's current EBITDA Margin % is 16.45%, which is 30% above median its own 10-year median of 12.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanjivani Paranterals stock overvalued right now?
Based on GuruFocus' analysis, Sanjivani Paranterals (BOM:531569) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹226.27, compared to a current price of ₹160.65 — trading 29% below its estimated fair value. The current EBITDA Margin % is 16.45%, which is 30% above median its 10-year median of 12.65 and 32.1% above the Drug Manufacturers industry median of 12.45. Sanjivani Paranterals' overall GF Score™ is 73/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sanjivani Paranterals (BOM:531569), the current EBITDA Margin % is 16.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanjivani Paranterals (BOM:531569) Overvalued in 2026?
Based on GuruFocus' analysis, Sanjivani Paranterals stock appears to be undervalued.
The current stock price of ₹160.65 is trading 29% below its estimated GF Value™ of ₹226.27.
GuruFocus considers Sanjivani Paranterals to be Modestly Undervalued.
Key valuation signals for BOM:531569:
EBITDA Margin %: 16.45% (30% above median its 10-year median of 12.65)
GF Value™: ₹226.27 vs. price of ₹160.65 (29% below fair value)
Industry Position: 32.1% above the Drug Manufacturers median (#379 of 961)
No single metric tells the full story. See the BOM:531569 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanjivani Paranterals Ltd is a pharmaceutical company principally engaged in providing pharmaceutical products and services. The company's main product range includes oral solids and small-volume parenteral and sterile powder formulations. The products offered by the company are anti-biotic, anti-emetic, anti-tuberculosis, anti-diabetic, anti-malarial, anti-fungal, calcium and vitamin, multivitamin, sedative, cardiovascular, anti-gout, and others. The company also provides Liquid Injection, Dry powder Injection, Capsules, Drops, and others. The firm sells its products in India and internationally.
73GF Score
Get the complete analysis for BOM:531569
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:531569 has been successfully added to your 
